Hypoxia in cervical cancer: from biology to imaging

Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP (2002) Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 20:680–687 Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Can Res 56:4509–4515 Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R (1999) Intratumoral pO(2)-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 53:99–104 Lyng H, Sundfor K, Trope C, Rofstad EK (2000) Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy. Clin Cancer Res 6:1104–1112 Barbera L, Thomas G (2009) Management of early and locally advanced cervical cancer. Semin Oncol 36:155–169 Overgaard J (2007) Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25:4066–4074 Hoskin PJ (2015) Hypoxia dose painting in prostate and cervix cancer. Acta Oncol 54:1259–1262 Milosevic MF, Townsley CA, Chaudary N, Clarke B, Pintilie M, Fan S, Glicksman R, Haider M, Kim S, MacKay H et al (2016) Sorafenib increases tumor hypoxia in cervical cancer patients treated with radiation therapy: results of a Phase 1 clinical study. Int J Radiat Oncol Biol Phys 94:111–117 Lai CH, Lin GG, Yen TC, Liu FY (2014) Molecular imaging in the management of gynecologic malignancies. Gynecol Oncol 135:156–162 Khiewvan B, Torigian DA, Emamzadehfard S, Paydary K, Salavati A, Houshmand S, Shamchi SP, Werner TJ, Aydin A, Roy SG et al (2016) Update of the role of PET/CT and PET/MRI in the management of patients with cervical cancer. Hell J Nucl Med 19:254–268 Nordsmark M, Loncaster J, Aquino-Parsons C, Chou SC, West C, Lindegaard JC, Havsteen H, Davidson SE, Raleigh JA, Overgaard J (2006) The prognostic value of pimonidazole and tumor pO(2) in human cervix carcinomas after radiation therapy: an international multi-center study. Radiother Oncol 78:S32 Sundfor K, Lyng H, Trope CG, Rofstad EK (2000) Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization. Radiother Oncol 54:101–107 Suzuki Y, Nakano T, Ohno T, Kato S, Niibe Y, Morita S, Tsujii H (2006) Oxygenated and reoxygenated tumors show better local control in radiation therapy for cervical cancer. Int J Gynecol Cancer 16:306–311 Wong RKW, Fyles A, Milosevic M, Pintilie M, Hill RP (1997) Heterogeneity of polarographic oxygen tension measurements in cervix cancer: an evaluation of within and between tumor variability, probe position, and track depth. Int J Radiat Oncol Biol Phys 39:405–412 Lyng H, Sundfor K, Rofstad EK (1997) Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia. Radiother Oncol 44:163–169 Raleigh JA, Chou SC, Bono EL, Thrall DE, Varia MA (2001) Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int J Radiat Oncol Biol Phys 49:569–574 Michiels C, Tellier C, Feron O (2016) Cycling hypoxia: a key feature of the tumor microenvironment. Biochim Biophys Acta Rev Cancer 1866:76–86 Ellingsen C, Ovrebo KM, Galappathi K, Mathiesen B, Rofstad EK (2012) pO(2) fluctuation pattern and cycling hypoxia in human cervical carcinoma and melanoma xenografts. Int J Radiat Oncol Biol Phys 83:1317–1323 Cairns RA, Hill RP (2004) Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Can Res 64:2054–2061 Cooper RA, West CML, Logue JP, Davidson SE, Miller A, Roberts S, Statford IJ, Honess DJ, Hunter RD (1999) Changes in oxygenation during radiotherapy in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 45:119–126 Fyles AW, Milosevic M, Pintilie M, Hill RP (1998) Cervix cancer oxygenation measured following external radiation therapy. Int J Radiat Oncol Biol Phys 42:751–753 Lyng H, Sundfor K, Rofstad EK (2000) Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis. Int J Radiat Oncol Biol Phys 46:935–946 Sakata KI, Someya M, Nagakura H, Nakata K, Oouchi A, Hareyama M, Satoh M (2006) A clinical study of hypoxia using endogenous hypoxic markers and polarographic oxygen electrodes. Strahlenther Onkol 182:511–517 Lyng H, Sundfor K, Trope C, Rofstad EK (1996) Oxygen tension and vascular density in human cervix carcinoma. Br J Cancer 74:1559–1563 West CML, Cooper RA, Loncaster JA, Wilks DP, Bromley M (2001) Tumor vascularity: a histological measure of angiogenesis and hypoxia. Can Res 61:2907–2910 Hockel S, Schlenger K, Vaupel P, Hockel M (2001) Association between host tissue vascularity and the prognostically relevant tumor vascularity in human cervical cancer. Int J Oncol 19:827–832 Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8:705–713 Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, West CML, Stratford IJ (2003) GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 104:85–91 Haugland HK, Vukovic V, Pintilie M, Fyles AW, Milosevic M, Hill RP, Hedley DW (2002) Expression of hypoxia-inducible factor-1 alpha in cervical carcinomas: correlation with tumor oxygenation. Int J Radiat Oncol Biol Phys 53:854–861 Hutchison GJ, Valentine HR, Loncaster JA, Davidson SE, Hunter RD, Roberts SA, Harris AL, Stratford IJ, Price PM, West CML (2004) Hypoxia-inducible factor lot expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 10:8405–8412 Jankovic B, Aquino-Parsons C, Raleigh JA, Stanbridge EJ, Durand RE, Banath JP, MacPhail SH, Olive PL (2006) Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry Part B Clin Cytometry 70B:45–55 Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CML (2001) Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Can Res 61:6394–6399 Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G (2000) Overexpression of hypoxia-inducible factor 1 alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Can Res 60:4693–4696 Huang ML, Chen Q, Xiao JP, Yao TT, Bian LJ, Liu CH, Lin ZQ (2014) Overexpression of hypoxia-inducible factor-1 alpha is a predictor of poor prognosis in cervical cancer: a clinicopathologic study and a meta-analysis. Int J Gynecol Cancer 24:1054–1064 Liao SY, Darcy KM, Randall LM, Tian CQ, Monk BJ, Burger RA, Fruehauf JP, Peters WA, Stock RJ, Stanbridge EJ (2010) Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 116:452–458 Bachtiary B, Schindl M, Potter R, Dreier B, Knocke TH, Hainfellner JA, Horvat R, Birner P (2003) Overexpression of hypoxia-inducible factor 1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9:2234–2240 Burri P, Djonov V, Aebersold DM, Lindel K, Studer U, Altermatt HJ, Mazzucchelli L, Greiner RH, Gruber G (2003) Significant correlation of hypoxia-inducible factor-1 alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56:494–501 Dellas K, Bache M, Pigorsch SU, Taubert H, Kappler M, Holzapfel D, Zorn E, Holzhausen HJ, Haensgen G (2008) Prognostic impact of HIF-1 alpha expression in patients with definitive radiotherapy for cervical cancer. Strahlenther Onkol 184:169–174 Huang XQ, Liu MM, Sun H, Wang FJ, Xie XX, Chen X, Su J, He YX, Dai YY, Wu HJ, Shen LF (2015) HK2 is a radiation resistant and independent negative prognostic factor for patients with locally advanced cervical squamous cell carcinoma. Int J Clin Exp Pathol 8:4054–4063 Iwasaki K, Yabushita H, Ueno T, Wakatsuki A (2015) Role of hypoxia-inducible factor-1 alpha, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer. Oncol Lett 10:1970–1978 Kim BW, Cho H, Chung JY, Conway C, Ylaya K, Kim JH, Hewitt SM (2013) Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry. J Transl Med 11(185):1–11 Mayer A, Hockel M, Wree A, Vaupel P (2005) Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers. Clin Cancer Res 11:2768–2773 Zhao YJ, Shen LF, Chen X, Qian YJ, Zhou Q, Wang Y, Li K, Liu MM, Zhang S, Huang XQ (2015) High expression of PKM2 as a poor prognosis indicator is associated with radiation resistance in cervical cancer. Histol Histopathol 30:1313–1320 Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8:851–864 Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes EK, Alsner J, Kristensen GB, Malinen E, Lyng H (2016) Integrative analysis of DCE-MRI and gene expression profiles in construction of a gene classifier for assessment of hypoxia-related risk of chemoradiotherapy failure in cervical cancer. Clin Cancer Res 22:4067–4076 Halle C, Andersen E, Lando M, Aarnes EK, Hasvold G, Holden M, Syljuasen RG, Sundfor K, Kristensen GB, Holm R et al (2012) Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. Can Res 72:5285–5295 Mujcic H, Nagelkerke A, Rouschop KMA, Chung S, Chaudary N, Span PN, Clarke B, Milosevic M, Sykes J, Hill RP et al (2013) Hypoxic Activation OF the PERK/eIF2 alpha arm of the unfolded protein response promotes metastasis through induction of LAMP3. Clin Cancer Res 19:6126–6137 Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, Domarkas J, Lord S, Baldry C, Gilbert FJ (2015) Imaging tumour hypoxia with positron emission tomography. Br J Cancer 112:238–250 Fang SW, Hong MT, Zhang H (2010) Positron emission tomography imaging of tumor hypoxia. Curr Med Imaging Rev 6:8–16 Imam SK (2010) Review of positron emission tomography tracers for imaging of tumor hypoxia. Cancer Biother Radiopharm 25:365–374 Varghese AJ, Whitmore GF (1980) Binding to cellular macromolecules as a possible mechanism for the cyto-toxicity of misonidazole. Can Res 40:2165–2169 Lee ST, Scott AM (2007) Hypoxia positron emission tomography imaging with F-18-fluoromisonidazole. Semin Nucl Med 37:451–461 Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA (2008) An imaging comparison of Cu-64-ATSM and Cu-60-ATSM in cancer of the uterine cervix. J Nucl Med 49:1177–1182 Vavere AL, Lewis JS (2007) Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 43:4893–4902 Holland JP, Lewis JS, Dehdashti F (2009) Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging 53:193–200 Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, Krohn KA, Griffin TW (1992) Imaging of hypoxia in human tumors with [F-18] fluoromisonidazole. Int J Radiat Oncol Biol Phys 22:199–212 Pinker K, Andrzejewski P, Baltzer P, Polanec SH, Sturdza A, Georg D, Helbich TH, Karanikas G, Grimm C, Polterauer S et al (2016) Multiparametric [F-18]fluorodeoxyglucose/[F-18]fluoromisonidazole positron emission tomography/magnetic resonance imaging of locally advanced cervical cancer for the non-invasive detection of tumor heterogeneity: a pilot study. PLoS One 11(5):e0155333 Busk M, Horsman MR, Jakobsen S, Keiding S, van der Kogel AJ, Bussink J, Overgaard J (2008) Imaging hypoxia in xenografted and murine tumors with F-18-fluoroazomycin arabinoside: a comparative study involving micropet, autoradiography, Po-2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys 70:1202–1212 Schuetz M, Schmid MP, Potter R, Kommata S, Georg D, Lukic D, Dudczak R, Kletter K, Dimopoulos J, Karanikas G, Bachtiary B (2010) Evaluating repetitive F-18-fluoroazomycin-arabinoside ((18)FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncol 49:941–947 Vercellino L, Groheux D, Thoury A, Delord M, Schlageter MH, Delpech Y, Barre E, Baruch-Hennequin V, Tylski P, Homyrda L et al (2012) Hypoxia imaging of uterine cervix carcinoma with F-18-FETNIM PET/CT. Clin Nucl Med 37:1065–1068 Le QT, Sutphin PD, Raychaudhuri S, Yu SCT, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59–67 Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ (2008) Assessing tumor hypoxia in cervical cancer by PET with Cu-60-labeled diacetyl-bis(N-4-methylthiosemicarbazone). J Nucl Med 49:201–205 Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ (2003) Assessing tumor hypoxia in cervical cancer by positron emission tomography with Cu-60-ATSM: relationship to therapeutic response—a preliminary report. Int J Radiat Oncol Biol Phys 55:1233–1238 Grigsby PW, Malyapa RS, Higashikubo R, Schwarz JK, Welch MJ, Huettner PC, Dehdashti F (2007) Comparison of molecular markers of hypoxia and imaging with Cu-60-ATSM in cancer of the uterine cervix. Mol Imag Biol 9:278–283 Dence CS, Ponde DE, Welch MJ, Lewis JS (2008) Autoradiographic and small-animal PET comparisons between F-18-FMISO, F-18-FDG, F-18-FLT and the hypoxic selective Cu-64-ATSM in a rodent model of cancer. Nucl Med Biol 35:713–720 O’Donoghue JA, Zanzonico P, Pugachev A, Wen BX, Smith-Jones P, Cai SD, Burnazi E, Finn RD, Burgman P, Ruan S et al (2005) Assessment of regional tumor hypoxia using F-18-fluoromisonidazole and Cu-64(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po-2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61:1493–1502 Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW (2006) Intertumoral differences in hypoxia selectivity of the PET imaging agent Cu-64(II)-diacetyl-bis(N-4-methylthiosemicarbazone). J Nucl Med 47:989–998 Grigsby PW (2008) The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging 8:146–155 Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, Eble M, Buell U, Reinartz P (2006) FDG—a marker of tumour hypoxia? A comparison with [F-18] fluoromisonidazole and pO(2)-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 33:1426–1431 Busk M, Horsman MR, Kristjansen PEG, van der Kogel AJ, Bussink J, Overgaard J (2008) Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer 122:2726–2734 Christian N, Deheneffe S, Bol A, De Bast M, Labar D, Lee JA, Gregoire V (2010) Is F-18-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer C-14-EF3 in animal tumor models. Radiother Oncol 97:183–188 Dierckx RA, de Wiele CV (2008) FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging 35:1544–1549 Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J (2012) Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 9:674–687 Cheng YX, Chen GT, Hong L, Zhou LM, Hu M, Li BS, Huang JL, Xia LB, Li CL (2013) How does hypoxia inducible factor-1 alpha participate in enhancing the glycolysis activity in cervical cancer? Ann Diagn Pathol 17:305–311 Park SI, Suh DS, Kim SJ, Choi KU, Yoon MS (2013) Correlation between biological marker expression and F-18-fluorodeoxyglucose uptake in cervical cancer measured by position emission tomography. Onkologie 36:169–174 Price JM, Robinson SP, Koh DM (2013) Imaging hypoxia in tumours with advanced MRI. Q J Nucl Med Mol Imaging 57:257–270 Hallac RR, Ding Y, Yuan Q, McColl RW, Lea J, Sims RD, Weatherall PT, Mason RP (2012) Oxygenation in cervical cancer and normal uterine cervix assessed using blood oxygenation level-dependent (BOLD) MRI at 3T. NMR Biomed 25:1321–1330 O’Connor JPB, Naish JH, Parker GJM, Waterton JC, Watson Y, Jayson GC, Buonaccorsi GA, Cheung S, Buckley DL, McGrath DM et al (2009) Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomarker of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys 75:1209–1215 Ciris PA, Balasubramanian M, Damato AL, Seethamraju RT, Tempany-Afdhal CM, Mulkern RV, Viswanathan AN (2016) Characterizing gradient echo signal decays in gynecologic cancers at 3T using a Gaussian augmentation of the monoexponential (GAME) model. J Magn Reson Imaging 44:1020–1030 Kim CK, Park SY, Park BK, Park W, Huh SJ (2014) Blood oxygenation level-dependent MR imaging as a predictor of therapeutic response to concurrent chemoradiotherapy in cervical cancer: a preliminary experience. Eur Radiol 24:1514–1520 Choi SH, Kim CK, Park JJ, Park BK (2016) Assessment of early therapeutic changes to concurrent chemoradiotherapy in uterine cervical cancer using blood oxygenation level-dependent magnetic resonance imaging. J Comput Assist Tomogr 40:730–734 Li XS, Fan HX, Fang H, Song YL, Zhou CW (2015) Value of R2*obtained from T2*-weighted imaging in predicting the prognosis of advanced cervical squamous carcinoma treated with concurrent chemoradiotherapy. J Magn Reson Imaging 42:681–688 Mahajan A, Engineer R, Chopra S, Mahanshetty U, Juvekar SL, Shrivastava SK, Desekar N, Thakura MH (2016) Role of 3T multiparametric-MRI with BOLD hypoxia imaging for diagnosis and post therapy response evaluation of postoperative recurrent cervical cancers. Eur J Radiol Open 3:22–30 Hasebroock KM, Serkova NJ (2009) Toxicity of MRI and CT contrast agents. Expert Opin Drug Metab Toxicol 5:403–416 Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT (2007) Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 8:63–74 Loncaster JA, Carrington BM, Sykes JR, Jones AP, Todd SM, Cooper R, Buckley DL, Davidson SE, Logue JP, Hunter RD, West CML (2002) Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 54:759–767 Lyng H, Vorren AO, Sundfor K, Taksdal I, Lien HH, Kaalhus A, Rofstad EK (2001) Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging. J Magn Reson Imaging 14:750–756 Haider MA, Milosevic M, Fyles A, Sitartchouk I, Yeung I, Henderson E, Lockwood G, Lee TY, Roberts TPL (2005) Assessment of the tumor microenvironment in cervix cancer using dynamic contrast enhanced CT, interstitial fluid pressure and oxygen measurements. Int J Radiat Oncol Biol Phys 62:1100–1107 Hawighorst H, Knapstein PG, Knopp MV, Weikel W, Brix G, Zuna I, Schonberg SO, Essig M, Vaupel P, van Kaick G (1998) Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Can Res 58:3598–3602 Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7:91–101 Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp M, Larsson HBW, Lee TY, Mayr NA, Parker GJM et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232 Andersen EKF, Hole KH, Lund KV, Sundfor K, Kristensen GB, Lyng HD, Malinen E (2013) Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome. Radiother Oncol 107:117–122 Kallehauge J, Nielsen T, Haack S, Peters DA, Mohamed S, Fokdal L, Lindegaard JC, Hansen DC, Rasmussen F, Tanderup K, Pedersen EM (2013) Voxelwise comparison of perfusion parameters estimated using dynamic contrast enhanced (DCE) computed tomography and DCE-magnetic resonance imaging in locally advanced cervical cancer. Acta Oncol 52:1360–1368 Kim SM, Haider MA, Milosevic M, Yeung IWT (2013) A comparison of dynamic contrast-enhanced CT and MR imaging-derived measurements in patients with cervical cancer. Clin Physiol Funct Imaging 33:150–161 Yang C, Stadler WM, Karczmar GS, Milosevic M, Yeung I, Haider MA (2010) Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT. Magn Reson Med 63:1601–1609 Andersen EKF, Hole KH, Lund KV, Sundfor K, Kristensen GB, Lyng H, Malinen E (2012) Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance. Int J Radiat Oncol Biol Phys 82:E485–E492 Lund KV, Simonsen TG, Hompland T, Kristensen GB, Rofstad EK (2015) Short-term pretreatment DCE-MRI in prediction of outcome in locally advanced cervical cancer. Radiother Oncol 115:379–385 Zahra MA, Tan LT, Priest AN, Graves MJ, Arends M, Crawford RAF, Brenton JD, Lomas DJ, Sala E (2009) Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int J Radiat Oncol Biol Phys 74:766–773 Hawighorst H, Weikel W, Knapstein PG, Knopp MV, Zuna I, Schonberg SO, Vaupel P, van Kaick G (1998) Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 4:2305–2312 Li XS, Fan HX, Zhu HX, Song YL, Zhou CW (2012) The value of perfusion CT in predicting the short-term response to synchronous radiochemotherapy for cervical squamous cancer. Eur Radiol 22:617–624 Mayr NA, Wang JZ, Zhang DQ, Grecula JC, Lo SS, Jaroura D, Montebello J, Zhang HL, Li KL, Lu LC et al (2010) Longitudinal changes in tumor perfusion pattern during the radiation therapy course and its clinical impact in cervical cancer. Int J Radiat Oncol Biol Phys 77:502–508 Yuh WTC, Mayr NA, Jarjoura D, Wu D, Grecula JC, Lo SS, Edwards SM, Magnotta VA, Sammet S, Zhang H et al (2009) Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer. Invest Radiol 44:343–350 Challapalli A, Carroll L, Aboagye EO (2017) Molecular mechanisms of hypoxia in cancer. Clin Transl Imaging 5:225–253 Cascini GL, Asabella AN, Notaristefano A, Restuccia A, Ferrari C, Rubini D, Altini C, Rubini G (2014) (124)Iodine: a longer-life positron emitter isotope-new opportunities in molecular imaging. Biomed Res Int 2014:672094. doi:10.1155/2014/672094 Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D, Hicks RJ (2007) Imaging of tumor hypoxia with [I-124] IAZA in comparison with [F-18] FMISO and [F-18]FAZA—first small animal PET results. J Pharm Pharm Sci 10:203–211 O’Donoghue JA, Guillem JG, Schoder H, Lee NY, Divgi CR, Ruby JA, Humm JL, Lee-Kong SA, Burnazi EM, Cai SD et al (2013) Pilot study of PET imaging of I-124-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer. Ejnmmi Res 3(42):1–10 Mullani NA, Herbst RS, O’Neil RG, Gould KL, Barron BJ, Abbruzzese JL (2008) Tumor blood flow measured by PET dynamic imaging of first-pass F-18-FDG uptake: a comparison with O-15-labeled water-measured blood flow. J Nucl Med 49:517–523 An YS, Kang DK, Jung YS, Han S, Kim TH (2015) Tumor metabolism and perfusion ratio assessed by 18F-FDG PET/CT and DCE-MRI in breast cancer patients: correlation with tumor subtype and histologic prognostic factors. Eur J Radiol 84:1365–1370 Apostolova I, Hofheinz F, Buchert R, Steffen IG, Michel R, Rosner C, Prasad V, Kohler C, Derlin T, Brenner W, Marnitz S (2014) Combined measurement of tumor perfusion and glucose metabolism for improved tumor characterization in advanced cervical carcinoma A PET/CT pilot study using [O-15]water and [F-18]fluorodeoxyglucose. Strahlenther Onkol 190:575–581 De Langen AJ, van den Boogaart VEM, Marcus JT, Lubberink M (2008) Use of (H2O)-O-15-PET and DCE-MRI to measure tumor blood flow. Oncologist 13:631–644 Malinen E, Rodal J, Knudtsen IS, Sovik A, Skogmo HK (2011) Spatiotemporal analysis of tumor uptake patterns in dynamic (18)FDG-PET and dynamic contrast enhanced CT. Acta Oncol 50:873–882 Yang DJ, Kim EE, Inoue T (2006) Targeted molecular imaging in oncology. Ann Nucl Med 20:1–11 Thoeny HC, Ross BD (2010) Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 32:2–16 Heo SH, Shin SS, Kim JW, Lim HS, Jeong YY, Kang WD, Kim SM, Kang HK (2013) Pre-treatment diffusion-weighted MR imaging for predicting tumor recurrence in uterine cervical cancer treated with concurrent chemoradiation: value of histogram analysis of apparent diffusion coefficients. Korean J Radiol 14:616–625 Marconi DG, Fregnani JHTG, Rossini RR, Netto AKBJ, Lucchesi FR, Tsunoda AT, Kamrava M (2016) Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation. BMC Cancer 16(556):1–9 Gladwish A, Milosevic M, Fyles A, Xie J, Halankar J, Metser U, Jiang HY, Becker N, Levin W, Manchul L et al (2016) Association of apparent diffusion coefficient with disease recurrence in patients with locally advanced cervical cancer treated with radical chemotherapy and radiation therapy. Radiology 279:158–166 Onal C, Erbay G, Guler OC (2016) Treatment response evaluation using the mean apparent diffusion coefficient in cervical cancer patients treated with definitive chemoradiotherapy. J Magn Reson Imaging 44:1010–1019 Liu Y, Bai RJ, Sun HR, Liu HD, Wang DH (2009) Diffusion-weighted magnetic resonance imaging of uterine cervical cancer. J Comput Assist Tomogr 33:858–862 Nakamura K, Joja I, Kodama J, Hongo A, Hiramatsu Y (2012) Measurement of SUVmax plus ADCmin of the primary tumour is a predictor of prognosis in patients with cervical cancer. Eur J Nucl Med Mol Imaging 39:283–290 McVeigh PZ, Syed AM, Milosevic M, Fyles A, Haider MA (2008) Diffusion-weighted MRI in cervical cancer. Eur Radiol 18:1058–1064 Lee EYP, Hui ESK, Chan KKL, Tse KY, Kwong WK, Chang TY, Chan Q, Khong PL (2015) Relationship between intravoxel incoherent motion diffusion-weighted MRI and dynamic contrast-enhanced MRI in tissue perfusion of cervical cancers. J Magn Reson Imaging 42:454–459 Zhou Y, Liu JY, Liu CR, Jia J, Li N, Xie LZ, Zhou ZY, Zhang ZH, Zheng DD, He W et al (2016) Intravoxel incoherent motion diffusion weighted MRI of cervical cancer—correlated with tumor differentiation and perfusiond. Magn Reson Imaging 34:1050–1056 Zhu L, Zhu LJ, Shi H, Wang HH, Yan J, Liu BR, Chen WB, He J, Zhou ZY, Yang XF, Liu T (2016) Evaluating early response of cervical cancer under concurrent chemo-radiotherapy by intravoxel incoherent motion MR imaging. BMC Cancer 16(79):1–8 Rey S, Schito L, Koritzinsky M, Wouters BG (2017) Molecular targeting of hypoxia in radiotherapy. Adv Drug Deliv Rev 109:45–62 Lambin P, van Stiphout RGPM, Starmans MHW, Rios-Velazquez E, Nalbantov G, Aerts HJWL, Roelofs E, van Elmpt W, Boutros PC, Granone P et al (2013) Predicting outcomes in radiation oncology-multifactorial decision support systems. Nat Rev Clin Oncol 10:27–40 Fjeldbo CS, Aarnes EK, Malinen E, Kristensen GB, Lyng H (2016) Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients. PLoS One 11(5):e0156259 Sovik A, Malinen E, Olsen DR (2009) Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys 73:650–658 Sturdza A, Potter R, Fokdal LU, Haie-Meder C, Tan LT, Mazeron R, Petric P, Segedin B, Jurgenliemk-Schulz IM, Nomden C et al (2016) Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 120:428–433 Xu HQ, Li B, Yu WJ, Wang H, Zhao XF, Yao YC, Huang DK (2013) Correlation between F-18-FDG uptake and the expression of glucose transporter-1 and hypoxia-inducible factor-1 in transplanted VX2 tumors. Nucl Med Commun 34:953–958 Li A, Andersen E, Lervåg C, Julin CH, Lyng H, Hellebust TP, Malinen E (2017) Dynamic contrast enhanced magnetic resonance imaging for hypoxia mapping and potential for brachytherapy targeting. Phys Imaging Radiat Oncol 2:1–6